Phase II DESTINY-Gastric01 trial of Enhertu versus chemotherapy met primary endpoint
27 January 2020 07:00 GMT Phase II DESTINY-Gastric01 trial of Enhertu versuschemotherapy met primary endpoint Trial met primary endpoint of objective response rate and key secondaryendpoint of overall survival in patients with previously treated HER2-positive metastatic gastric cancer High-level results from the positive registrational Phase II trial DESTINY-Gastric01 showed AstraZeneca's and Daiichi Sankyo Company, Limited (Daiichi Sankyo)'s Enhertu (trastuzumab deruxtecan), achieved a statistically significant and clinically meaningful improvement in objective response